NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NGNE NEUROGENE INC

Pre-Market Trading 04-09 07:10:25 EDT

7.34

-0.52

-6.68%

盘前7.13

-0.21-2.86%

04:05 EDT

High8.40	Low6.88	Vol953.51K
Open8.28	D1 Closing7.87	Amplitude19.36%
Mkt Cap109.58M	Tradable Cap40.70M	Total Shares14.93M
T/O6.83M	T/O Rate17.19%	Tradable Shares5.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":7.34,"timestamp":1744142400000,"preClose":7.865,"halted":0,"volume":953510,"hourTrading":{"tag":"盘前","latestPrice":7.13,"preClose":7.34,"latestTime":"04:05 EDT","volume":1,"amount":7.13,"timestamp":1744185935998},"delay":0,"floatShares":5545466,"shares":14929566,"eps":-4.28,"marketStatus":"Pre-Market Trading","change":-0.525,"latestTime":"04-09 07:10:25 EDT","open":8.28,"high":8.398,"low":6.875,"amount":6825819.570239999,"amplitude":0.193643,"askPrice":7.96,"askSize":100,"bidPrice":6.81,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-4.28,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744205400000},"marketStatusCode":1,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":7.34,"preHourTrading":{"tag":"盘前","latestPrice":7.13,"preClose":7.34,"latestTime":"04:05 EDT","volume":1,"amount":7.13,"timestamp":1744185935998},"postHourTrading":{"tag":"盘后","latestPrice":7,"preClose":7.34,"latestTime":"19:31 EDT","volume":3405,"amount":24276.76,"timestamp":1744155088577},"volumeRatio":2.314251415016512,"impliedVol":1.1831,"impliedVolPercentile":0.8282},"requestUrl":"/m/hq/s/NGNE","defaultTab":"news","newsList":[{"id":"2524446541","title":"Neurogene announces peer-reviewed publication of EXACT transgene technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2524446541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524446541?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 04:06","pubTimestamp":1743624400,"startTime":"0","endTime":"0","summary":"The company states: “Neurogene (NGNE) announced a peer-reviewed publication on its EXACT transgene regulation technology. The preclinical studies d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-announces-peer-reviewed-publication-of-exact-transgene-technology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-announces-peer-reviewed-publication-of-exact-transgene-technology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2524491531","title":"Biotech stocks slide as Marks resignation seen being negative for sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2524491531","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524491531?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 23:50","pubTimestamp":1743522637,"startTime":"0","endTime":"0","summary":"Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors.Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.“NOT GOOD” FOR BIOTECH SECTOR: RBC Capital believes the resignation of the head of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, is “not good for the biotech industry even beyond vaccines.” Marks had been a key advocate for more flexible, efficient approval processes for drugs, particularly those for orphan diseases such as gene therapies, the firm tells investors in a research note.PRICE ACTION: In mornin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-stocks-slide-marks-resignation-155037694.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stocks-slide-marks-resignation-155037694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823416689.USD","MGX","IE0002141913.USD","LU0058720904.USD","LU2468319806.SGD","BEAM","KPTI","BK4007","MRNA","NTLA","RCKTW","LU0320765992.SGD","BK4578","GILD","LU1069344957.HKD","IE00B4R5TH58.HKD","PTCT","IE0009355771.USD","CRSP","LU1571399168.USD","LU2362540622.SGD","NGNE","VERV","BK4139","IE00BZ9MQY76.HKD","REGN","BK4532","PCRX","MGTX","LU1035775433.USD","RNA","LU2023250504.SGD","BK4568","FDMT","RCKT","PRME","LEGN","SRPT","TSHA","RGNX","LU2462157665.USD","VRTX","GLPG","LU1066053197.SGD","LU1430594728.SGD","DTIL","LU1066051498.USD","IE00B3T34201.USD","BK4551","LU0417517546.SGD","IE00BFTCPJ56.SGD","DYN"],"gpt_icon":1},{"id":"2522750884","title":"Neurogene files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2522750884","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522750884?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 03:18","pubTimestamp":1742930338,"startTime":"0","endTime":"0","summary":"16:35 EDT Neurogene (NGNE) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-files-300m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-files-300m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2522881034","title":"Neurogene price target lowered to $38 from $46 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2522881034","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522881034?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:59","pubTimestamp":1742929142,"startTime":"0","endTime":"0","summary":"Baird analyst Joel Beatty lowered the firm’s price target on Neurogene (NGNE) to $38 from $46 and keeps an Outperform rating on the shares. The fir...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-lowered-to-38-from-46-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-lowered-to-38-from-46-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2522291260","title":"Neurogene Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522291260","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522291260?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:32","pubTimestamp":1742902320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 07:32 ET (11:32 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2522085674","title":"Neurogene Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522085674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522085674?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 05:33","pubTimestamp":1742851983,"startTime":"0","endTime":"0","summary":"Neurogene Inc reports results for the quarter ended December 31 - Earnings SummaryNeurogene Inc NGNE.OQ reported a quarterly adjusted loss of 99 cents per share for the quarter ended December 31, high","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL5N3Q7201:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2522088469","title":"Neurogene Q4 Net Profit $(19.5)M Down From $2.4M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2522088469","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522088469?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:53","pubTimestamp":1742849638,"startTime":"0","endTime":"0","summary":"Neurogene Q4 Net Profit $(19.5)M Down From $2.4M YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44465862/neurogene-q4-net-profit-19-5-m-down-from-2-4m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2522263700","title":"BRIEF-Neurogene Inc Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522263700","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522263700?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:38","pubTimestamp":1742848737,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Inc Files For Mixed Shelf Offering Of Up To $300 Million - SEC FilingMarch 24  - Neurogene Inc NGNE.O:NEUROGENE INC: FILES FOR MIXED SHELF OFFERING OF UP TO $300 MILLION - SEC FILINGSource text: [ID:n0001628280-25-014521]Further company coverage: NGNE.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2522700424","title":"Neurogene Inc: Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522700424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522700424?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:35","pubTimestamp":1742848557,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2522707976","title":"BRIEF-Neurogene FY Net Income USD -75.144 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707976?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:10","pubTimestamp":1742847045,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene FY Net Income USD -75.144 Million\n\n\nMar 24 (Reuters) - Neurogene FY operating income USD -82.605 million.\n\nFY operating expenses USD 83.53 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nPLX3DFE3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2522707970","title":"Neurogene Inc - Regulatory Update on Ngn-401 Trial Plans Expected in H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707970?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:10","pubTimestamp":1742847000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nPLX3DFE3C:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2522707942","title":"Neurogene Inc: Cash Runway Into Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707942?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:10","pubTimestamp":1742847000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nPLX3DFE3C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2522707613","title":"Neurogene FY Operating Income USD -82.605 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707613?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:10","pubTimestamp":1742847000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nPLX3DFE3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2522707697","title":"Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707697?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:10","pubTimestamp":1742847000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA5TNLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2522770718","title":"Press Release: Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522770718","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522770718?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:10","pubTimestamp":1742847000,"startTime":"0","endTime":"0","summary":"Remains on track to provide regulatory update on registrational trial plans with NGN-401 for Rett syndrome in the first half of 2025. Continues to expect to share additional interim clinical data from NGN-401 Phase 1/2 trial in the second half of 2025. Received PRIME designation for NGN-401 from the European Medicines Agency. Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates.Fourth Quarter 2024 and Recent Highlights, and Anticipated Milestones. -- Protocol amended and submitted to U.S. Food and Drug Administration . participants expected to be dosed during the first half of the year","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0971096721.USD","IE00BKVL7J92.USD","LU0149725797.USD","BK4555","TM","03160","LU1363072403.SGD","BK4588","LU0170899867.USD","BK4604","BK4099","BK4585","LU0882574139.USD","BK4139","IE00BHPRN162.USD","CMC","BK4006","IE00B1BXHZ80.USD","LU0267386448.USD","IE00BZ1G4Q59.USD","NGNE"],"gpt_icon":0},{"id":"2521037934","title":"North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2521037934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521037934?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 18:02","pubTimestamp":1742551320,"startTime":"0","endTime":"0","summary":"The euphoria from the Federal Reserve's policy meeting didn't last long.Stock futures were lower Friday as attention shifted from the Fed to the prospect of further tariffs.Trump said in a social media post that the planned imposition of reciprocal tariffs on April 2 would be \"Liberation Day\" in the U.S.\"We maintain our view that the FOMC outcome was effectively a one-day move, with minimal legacy in terms of immediate direction. That said, we also view the FOMC outcome as a whole as nodding towards dovishness, but with numerous caveats,\" ING said.Quantum-computing stocks  are likely to be in focus after suffering steep falls on Thursday as investors appeared unimpressed by their contributions to Nvidia's Quantum Day at its GTC developers' event.The market also faces a test as an estimated $4.5 trillion in options contracts expire, which could increase volatility.FedEx fell 5.1% off hours after it cut its outlook for the year.Lennar management warned investors of a weak housing market.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDX","US30Y.BOND","SMXT","DM","OLMA","NVDA","NVDS","US2Y.BOND","US5Y.BOND","FBLG","PRPH","US10Y.BOND","DXYN","PURE","NVDY","NVD3.UK","MPU","SNVD.UK","AFG","NVDD","XOMA","US12M.BOND","US6M.BOND","ATXI","FBRX","IRD","IMNM","ZBIO","NVDU","ET","2NVD.UK","SGMA","3NVD.UK","BPTH","NVIW.SI","NVDS.UK","JVA","NGNE","GORV","US7Y.BOND","CKPT","BOLD","USAU","NVD2.UK","NVDL","IMRX","ADVM","CCL","US3Y.BOND"],"gpt_icon":1},{"id":"2513725817","title":"Neurogene to Participate in Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2513725817","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513725817?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 20:30","pubTimestamp":1740400200,"startTime":"0","endTime":"0","summary":"NEW YORK, February 24, 2025----Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:. TD Cowen 45th Annual Health Care ConferenceFormat: Management will participate in a fireside chat and investor meetingsDate: Monday, March 3 at 9:50 a.m. ET. Leerink Global Healthcare ConferenceFormat: Management will participate in a fireside chat and investor meetingsDate: Monday, March 10 at 1:00 p.m. ET. Stifel Virtual CNS ForumFormat: Management will participate in a fireside chatDate: Wednesday, March 19 at 9:30 a.m. ET. Live webcasts of the fireside chats will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the events will also be available for a limited time.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogene-participate-upcoming-conferences-123000601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2511031671","title":"Neurogene Insiders Placed Bullish Bets Worth US$1.46m","url":"https://stock-news.laohu8.com/highlight/detail?id=2511031671","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511031671?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 20:45","pubTimestamp":1739623502,"startTime":"0","endTime":"0","summary":"Quite a few insiders have dramatically grown their holdings in Neurogene Inc.  over the past 12 months. An insider's optimism about the company's prospects is a positive sign.Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.The Last 12 Months Of Insider Transactions At Neurogene. The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Neurogene we think they are probably pretty confident of a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogene-insiders-placed-bullish-bets-124502893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2510851137","title":"Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510851137","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510851137?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 20:45","pubTimestamp":1739191551,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene (NGNE – Research Report) today and set a price target of $46.00. The comp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-neurogene-ngne-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-neurogene-ngne-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","SF"],"gpt_icon":0},{"id":"2491361963","title":"William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491361963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491361963?lang=en_us&edition=full_marsco","pubTime":"2024-12-13 00:26","pubTimestamp":1734020769,"startTime":"0","endTime":"0","summary":"In a report released today, Sami Corwin from William Blair maintained a Buy rating on Neurogene (NGNE – Research Report). The company’s shares open...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-reaffirms-their-buy-rating-on-neurogene-ngne?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-reaffirms-their-buy-rating-on-neurogene-ngne?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurogene.com","stockEarnings":[{"period":"1week","weight":-0.2398},{"period":"1month","weight":-0.5752},{"period":"3month","weight":-0.6584},{"period":"6month","weight":-0.8476},{"period":"1year","weight":-0.8236},{"period":"ytd","weight":-0.6789}],"compareEarnings":[{"period":"1week","weight":-0.115},{"period":"1month","weight":-0.1379},{"period":"3month","weight":-0.1578},{"period":"6month","weight":-0.1383},{"period":"1year","weight":-0.0429},{"period":"ytd","weight":-0.1529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.051789},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.050266},{"month":3,"riseRate":0.454545,"avgChangeRate":0.037124},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.13142},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.011201},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.067793},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.101505},{"month":8,"riseRate":0.909091,"avgChangeRate":0.860852},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.065613},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.066641},{"month":11,"riseRate":0.454545,"avgChangeRate":0.035001},{"month":12,"riseRate":0.636364,"avgChangeRate":0.162965}],"exchange":"NASDAQ","name":"NEUROGENE INC","nameEN":"NEUROGENE INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.2","shortVersion":"4.32.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEUROGENE INC,NGNE,NEUROGENE INC股票,NEUROGENE INC股票老虎,NEUROGENE INC股票老虎国际,NEUROGENE INC行情,NEUROGENE INC股票行情,NEUROGENE INC股价,NEUROGENE INC股市,NEUROGENE INC股票价格,NEUROGENE INC股票交易,NEUROGENE INC股票购买,NEUROGENE INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}